Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced encouraging preclinical data of AV-412, a novel, next generation oral tyrosine kinase inhibitor of EGFR/HER2 using AVEO's unique EGFR mutant and drug-resistant lung cancer tumor models. The results from the preclinical study showed that AV-412 is greater than 10 times more potent than erlotinib in genetically engineered lung tumor models with the EGFR L858R mutation, producing rapid and complete tumor regression at a daily dose of 1 mg/kg. Additionally, AV-412 is also active against tumors carrying the EGFR kinase-resistance mutation EGFR L858R/T790M. These data were presented today in the EGFR Inhibition poster session at the 100th American Association for Cancer Research (AACR) Annual Meeting.

The molecularly targeted drugs - erlotinib (Tarceva(R)) and gefitinib (Iressa(R)) - inhibit EGFR kinase activity and are important therapies for patients with non-small cell lung cancer; however, recent clinical observations from independent groups suggest that lung cancer patients harboring the EGFR L858R mutation (approximately 44 percent of all EGFR mutants) exhibit poorer response rates, progression free survival and overall survival after treatment with EGFR kinase inhibitors when compared with patients harboring other EGFR mutations. This suggests the need for inhibitors that are more effective against patients with EGFR L858R mutations. In addition, resistance to EGFR kinase inhibitors uniformly develops over time often due to the acquisition of resistance mutations within the EGFR gene. Erlotinib and gefitinib have no effect on the EGFR L858R/T790M double mutant, which is estimated to account for approximately 50 percent of all drug resistance in EGFR mutant non-small cell lung cancer - representing a key unmet medical need.






Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:10/22/2014)... FAIRFIELD, N.J. , Oct. 22, 2014 /PRNewswire/ ... a major transformation in the pain market, according ... Pain Insights, Inc., a firm providing market research ... management. Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... a scheduling change for hydrocodone combination products from ...
(Date:10/22/2014)... Vernak, RPh, of Vernak Farms Pharmacy in ... George Roentsch Scholarship by the Professional Compounding Centers of ... Houston during PCCA,s International Seminar, held October ... independent pharmacist and PCCA member who embodies the innovative ... well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... Calif., May 27 Epeius Biotechnologies,( http://www.epeiusbiotech.com ) ... Feasibility Study of sequential targeted gene delivery -- ... will be presented at the,ASCO meetings in Chicago ... 2008).,Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles,bearing a ...
... in high risk node-negative, population to show ... BRIDGEWATER, N.J., May 27 Sanofi-aventis ... de Mama) announced today,that for women with ... (post surgery) with Taxotere(R) (docetaxel) Injection,Concentrate as ...
Cached Medicine Technology:TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 2TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 2Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 4Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 5
(Date:10/22/2014)... (PRWEB) October 22, 2014 On October ... Minds featuring skin diseases both fictional and real. ... (CEHMDF), a nonprofit organization committed to advocacy and philanthropy ... CBS will take the opportunity to impart truth and ... , There are many misconceptions about Morgellons ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... a recent study researchers find people who get only four hours ... turn could lead to weight gain. ,An investigation was ... were measured before the study started, after they had slept about ... slept about 10 hours a night for two nights. Levels of ...
... of the existing drugs on the market are losing ... soil bacteria hence researchers feel that the ocean is ... ,More than 1 million microorganisms fill every milliliter ... treatment for some of our deadliest diseases. Many marine ...
... God willing, in about a month’s time from now five-year-old ... return home to Baghdad as normal children.// Part of a ... to surgically correct their complicated cardiac problems by the Much ... babies, these two underwent assessment this evening by a paediatric ...
... Parkinson’s disease is a neurological condition that can cause slowness ... // both of these problems say researchers. A pulse of ... movement. This is done inorder to improve stiffness in patients. ... magnetic stimulation. ,For nearly 15 years, Criner has dealt ...
... risks and benefits of using CT scanning for young ... more than 3,000 men who received radiation therapy before ... tested at age 18 years or 19 years. Researchers ... ,Results of the study showed boys who received ...
... Reports suggest as many as 14 percent of pregnant ... of women use antidepressants during pregnancy. Studies involving infants ... shown few ill effects, so most doctors believe these ... most studies have only compared major outcomes, such as ...
Cached Medicine News:
... SES ("SES") is a surgical/ mechanical device ... layer of the cornea above Bowman's layer. ... alcohol currently used during LASEK to delaminate ... alcohol and providing a 'minimal-touch' surgical approach, ...
... You told us you wanted a ... installations and a lightweight portable for mobile ... XLTEK listened, and we answered with Protektor, our leading-edge, ... Both configurations feature XLTEK’s ruggedness, ...
... Creating more efficiency for high volume laboratories, ... extended walk away time. This high-speed analyzer ... to 1600 photometric test results per hour ... up to 51 tests on-board. Consolidate with ...
... size fits all plug. Once inserted into the punctum, ... it hydrates, Form Fit increases in size until it ... perfect fit. ,The Form Fit plug is made ... pliable, gelatinous material when it contacts tear film. The ...
Medicine Products: